- Investing.com
Promising Myeloma Therapy | Arcellx's anito-cel shows potential best-in-class efficacy and safety in multiple myeloma treatment, with 97% overall response rate in clinical trials |
Market Disruption Ahead | Analysts project CAR-T therapies could capture 30% of multiple myeloma market, positioning Arcellx for significant growth in a competitive landscape |
Financial Horizon | Despite current losses, Arcellx maintains strong liquidity. Analysts forecast EPS of -$1.47 for FY 2023, -$1.53 for FY 2024, and -$4.27 for FY 2025 |
Bullish Outlook | Analysts maintain strong buy consensus with high target of $134. Barclays and Canaccord set price targets at $115 and $121, respectively |
Metrics to compare | ACLX | Peers Peers - average of corresponding metrics from companies closely matching ACLX: | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipACLXPeersSector |
|---|---|---|---|---|
P/E Ratio | −29.5x | 0.0x | −0.4x | |
PEG Ratio | 0.29 | 0.00 | 0.00 | |
Price/Book | 16.8x | 0.0x | 2.6x | |
Price / LTM Sales | 302.9x | 0.0x | 3.0x | |
Upside (Analyst Target) | −0.1% | 0.0% | 57.3% | |
Fair Value Upside | Unlock | 0.0% | 8.9% | Unlock |